I agree. You’d have to think this deal would be months in the making. The Carlyle Group must be confident in the prospects of Opt-302 to outlay this sort of money given their investment, and any subsequent return is reliant on binary outcomes i.e. Opt-302 phase III trials need to be successful to gain FDA approval for commercialisation, and in addition if Opt -302 gets to market it will need to achieve significant sales traction for that return to be fully realised.
On another note my thoughts are this deal would appear to reduce even further the likelihood of a big pharma takeover of Opthea as it has to all intents and purposes by its very nature added a significant premium to the value of the company.
Must be about time for an update on how recruitment into the phase III trials is going. Maybe it will coincide with the upcoming equity announcement.
I agree. You’d have to think this deal would be months in the...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.005(1.43%) |
Mkt cap ! $376.5M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 34.5¢ | $232.4K | 666.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 906562 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 35109 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |